NCT06461377View on ClinicalTrials.gov

The Ameliorative Effects of GLP-1RA on Diabetic Cardiac Autonomatic Neuropathy

PHASE4RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 13, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Type 2 DiabetesDiabetes With Diabetic Autonomic Neuropathy (Diagnosis)
Interventions
DRUG

Glucagon-like peptide-1 receptor agonist：Semaglutide

The GLP-1RA intervention group was given subcutaneous injection of GLP-1RA for 3 months, while the control group was not given GLP-1RA intervention

Trial Locations (1)

210029

RECRUITING

the First Affiliated Hospital of Nanjing Medical University, Nanjing

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER